Search

Search results

101 results found

Contact

Chief of the Division of Clinical Informatics, BIDMC Yuri Quintan, PhD, yquintan@bidmc.harvard.edu Telephone: (617) 278-8162 Research Assistant Ava Homiar - ahomiar@bidmc.harvard.edu Address 133 Brookline Avenue, HVMA Annex, Suite 2200, Boston, MA 02215 Subscribe DCI mailing list for news and events

Funding

JDRF, 3-SRA-2020-894-S-B - Kissler (PI) 2020-2023 Evaluating the therapeutic potential of gene modifications that protect beta cells against autoimmunity R01DK120445, NIDDK - Kissler (PI) 2021-2025 Functional validation of gene modifications that protect beta cells against autoimmunity identified by...

Perinatal mental health

Perinatal mood disorders, including post-partum depression, are prevalent worldwide. Although a diverse array of effective treatments for perinatal mood disorders are known, few women in need will access them. When mental health goes unsupported in mothers it is detrimental first and foremost to...

Two Common Oculoplastics Disorders

Primary Acquired Nasolacrimal Duct Obstruction (PANDO) PANDO is a condition in which chronic inflammation and scarring block the tear drainage system without another identifiable cause for the obstruction, such as trauma, tumor, etc. Patients with PANDO usually seek help when tears overflow...

eye Insights Issue 10: Idiopathic Intracranial Hypertension

In this issue of eye Insights, we take a close look at idiopathic intracranial hypertension (IIH). You'll find key information about how IIH is diagnosed and treated. Inside: Message from the Editor-in-Chief What is Idiopathic Intracranial Hypertension? How is a Patient Diagnosed? What are the...

Message from the Editor-in-Chief

Dear Colleagues, In this issue of eye Insights, we take a close look at idiopathic intracranial hypertension (IIH). Inside, you’ll find key information about how IIH is diagnosed and treated as well as further reading. IIH is becoming more prevalent due to increasing rates of obesity in the United...

What are the Treatment Options?

Acetazolamide The first-line medical therapy is acetazolamide, which reduces CSF production by the choroid plexus. In the recent IIH Treatment Trial, acetazolamide, in addition to weight loss, was found to be more effective than weight loss alone in patients with IIH and mild visual loss. The...

Don't Let Glaucoma Rob Your Patients of Vision

Nearly half of Americans who currently have glaucoma are unaware of their condition. Why? Most types of glaucoma are painless, with no feelings of discomfort. Glaucoma typically affects peripheral vision first, so many people remain unaware of the disease until their central vision is affected...